Upfront BRAF/MEK inhibitors for treatment of high-grade glioma: A case report and review of the literature.

ABSTRACT:

Background

High-grade gliomas (HGG) with BRAFV600E mutation represent a unique subset of central nervous system tumors. Targeted therapies including BRAF and MEK inhibitors are now being explored as possible new treatment options.

Methods

We report an 18-year-old female with a grade 3 pleomorphic xanthoastrocytoma treated upfront with dabrafenib and trametinib. We also conducted a systematic literature review of patients with HGG and BRAFV600E mutations treated with BRAF inhibitors.

Results

Despite local recurrences resected surgically, the patient has been on dabrafenib and trametinib for more than 54 months. Thirty-two patients with HGG and BRAFV600E mutations treated with BRAF inhibitors were retrieved through our systematic review of the liter

SUBMITTER: Arbour G 

PROVIDER: S-EPMC9772816 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature